Questions about biosimilar interchangeability remain

Biosimilars generic

Questions about biosimilar interchangeability remain. At GPhA’s first biosimilars conference this week, Ronny Gal, a specialty pharmaceuticals analyst at Sanford Bernstein, said that interchangeability “remains an open question.” Gal specifically noted that an “interchangeable” designation will make certain biosimilars seem superior to others, even if the FDA attempts to make it clear that the interchangeable drug is “no more effective or safe than other biosimilars for the same reference product.” Gal also warned that the interchangeable designation could confuse patients. However, Momenta Pharmaceuticals CEO Craig Wheeler said that he believed the perception of higher quality ascribed to interchangeable biosimilars could present opportunities and an economic advantage.

Read the source article at

About the Author

Related Posts

Leave a Reply